{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEETS\tDollars in Millions, Except Share and Per Share Data\tDecember 31,\tASSETS\t2021\t2020\tCurrent Assets:\tCash and cash equivalents\t$\t13,979\t$\t14,546\tMarketable debt securities\t2,987\t1,285\tReceivables\t9,369\t8,501\tInventories\t2,095\t2,074\tOther current assets\t4,832\t3,786\tTotal Current Assets\t33,262\t30,192\tProperty, plant and equipment\t6,049\t5,886\tGoodwill\t20,502\t20,547\tOther intangible assets\t42,527\t53,243\tDeferred income taxes\t1,439\t1,161\tMarketable debt securities\t \t433\tOther non-current assets\t5,535\t7,019\tTotal Assets\t$\t109,314\t$\t118,481\tLIABILITIES\tCurrent Liabilities:\tShort-term debt obligations\t$\t4,948\t$\t2,340\tAccounts payable\t2,949\t2,713\tOther current liabilities\t13,971\t14,027\tTotal Current Liabilities\t21,868\t19,080\tDeferred income taxes\t4,501\t5,407\tLong-term debt\t39,605\t48,336\tOther non-current liabilities\t7,334\t7,776\tTotal Liabilities\t73,308\t80,599\tCommitments and contingencies\tEQUITY\tBristol-Myers Squibb Company Shareholders  Equity:\tPreferred stock, $2 convertible series, par value $\t1\tper share: Authorized\t10\tmillion shares; issued and outstanding\t3,484\tin 2021 and\t3,484\tin 2020, liquidation value of $\t50\tper share\t \t \tCommon stock, par value of $\t0.10\tper share: Authorized\t4.5\tbillion shares;\t2.9\tbillion issued in 2021 and 2020\t292\t292\tCapital in excess of par value of stock\t44,361\t44,325\tAccumulated other comprehensive loss\t(\t1,268\t)\t(\t1,839\t)\tRetained earnings\t23,820\t21,281\tLess cost of treasury stock  \t747\tmillion common shares in 2021 and\t679\tmillion common shares in 2020\t(\t31,259\t)\t(\t26,237\t)\tTotal Bristol-Myers Squibb Company Shareholders  Equity\t35,946\t37,822\tNoncontrolling interest\t60\t60\tTotal Equity\t36,006\t37,882\tTotal Liabilities and Equity\t$\t109,314\t$\t118,481\tThe accompanying notes are an integral part of these consolidated financial statements.\t74\tBRISTOL-MYERS SQUIBB COMPANY\tCONSOLIDATED STATEMENTS OF CASH FLOWS\tDollars in Millions\tYear Ended December 31,\t2021\t2020\t2019\tCash Flows From Operating Activities:\tNet earnings/(loss)\t$\t7,014\t$\t(\t8,995\t)\t$\t3,460\tAdjustments to reconcile net earnings/(loss) to net cash provided by operating activities:\tDepreciation and amortization, net\t10,686\t10,380\t1,746\tDeferred income taxes\t(\t1,393\t)\t983\t(\t924\t)\tStock-based compensation\t583\t779\t441\tImpairment charges\t1,207\t1,203\t199\tPension settlements and amortization\t35\t43\t1,688\tDivestiture gains and royalties\t(\t684\t)\t(\t699\t)\t(\t1,855\t)\tIPRD charge - MyoKardia acquisition\t \t11,438\t \tAsset acquisition charges\t1,157\t1,099\t63\tEquity investment gains, net\t(\t745\t)\t(\t1,228\t)\t(\t275\t)\tContingent consideration fair value adjustments\t(\t542\t)\t(\t1,757\t)\t523\tOther adjustments\t142\t(\t177\t)\t(\t26\t)\tChanges in operating assets and liabilities:\tReceivables\t(\t1,054\t)\t(\t646\t)\t752\tInventories\t13\t2,672\t463\tAccounts payable\t245\t188\t229\tRebates and discounts\t863\t1,189\t591\tIncome taxes payable\t(\t1,063\t)\t(\t2,305\t)\t907\tOther\t(\t257\t)\t(\t115\t)\t228\tNet Cash Provided by Operating Activities\t16,207\t14,052\t8,210\tCash Flows From Investing Activities:\tSale an"
        ],
        "timestamp": "2025-01-21_09-31-10"
    }
}